Bi-shRNAEWS-FLI-Type-1-LPX

Drug Profile

Bi-shRNAEWS-FLI-Type-1-LPX

Alternative Names: pbi-functional short hairpin RNA EWS/FLI2 type 1 lipoplex; pbi-functional shRNA EWS-FLI2 type 1 lipoplex; pbi-shRNA™ EWS/FLI1 Type 1 LPX

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gradalis
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ewing's sarcoma

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Ewing's Sarcoma (Late-stage disease, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT02736565)
  • 12 Apr 2016 Strike Bio and Gradalis plan a phase I trial for Ewing's sarcoma (Late-stage disease, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT02736565)
  • 04 Apr 2016 Preclinical trials in Ewing's Sarcoma in USA (IV) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top